$NVOS
Novo Integrated Sciences, Inc. Stock $nvos

$nvos Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000149315223044893 Filed on December 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$3.891M	$3.303M	$12.57M
YoY Change	13.8%	-71.86%	7.11%
Cost Of Revenue	$1.947M	$2.375M	$7.619M
YoY Change	15.92%	-65.77%	9.81%
Gross Profit	$1.944M	$928.2K	$4.953M
YoY Change	11.76%	-80.66%	3.2%
Gross Profit Margin	49.96%	28.1%	39.39%
Selling, General & Admin	$5.262M	$4.022M	$13.51M
YoY Change	32.15%	-72.04%	-6.11%
% of Gross Profit	270.66%	433.33%	272.7%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$72.60K	$582.8K	$292.0K
YoY Change	20.92%	-13.0%	-9.6%
% of Gross Profit	3.73%	62.78%	5.9%
Operating Expenses	$5.262M	$4.022M	$13.51M
YoY Change	32.15%	-72.04%	-54.72%
Operating Profit	-$3.318M	-$3.094M	-$8.553M
YoY Change	47.98%	-67.72%	-65.82%
Interest Expense	-$690.9K	-$715.9K	$360.6K
YoY Change	-513.12%	-91.1%	-77.38%
% of Operating Profit
Other Income/Expense, Net	-$1.343M	$607.6K	-$4.716M
YoY Change	-20.75%		-41.35%
Pretax Income	-$4.661M	-$3.202M	-$13.27M
YoY Change	18.39%	-90.32%	-59.87%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$4.680M	-$3.160M	-$13.21M
YoY Change	18.93%	-90.38%	-59.77%
Net Earnings / Revenue	-120.28%	-95.68%	-105.11%
Basic Earnings Per Share	-$0.28		-$1.30
Diluted Earnings Per Share	-$0.28	-$0.21	-$1.30
COMMON SHARES
Basic Shares Outstanding	17.29M shares	148.4M shares	10.17M shares
Diluted Shares Outstanding	16.73M shares		10.17M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.640M	$416.3K	$416.3K
YoY Change	86.64%	-80.89%	-80.89%
Cash & Equivalents	$1.640M	$416.3K	$416.3K
Short-Term Investments
Other Short-Term Assets	$213.8K	$346.2K	$346.2K
YoY Change	-61.47%	-39.41%	-39.41%
Inventory	$1.271M	$1.107M	$1.107M
Prepaid Expenses
Receivables	$2.636M	$1.467M	$1.467M
Other Receivables	$1.048M	$1.052M	$1.052M
Total Short-Term Assets	$6.809M	$4.388M	$4.388M
YoY Change	52.75%	-23.44%	-23.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.307M	$5.390M	$7.374M
YoY Change	-4.62%	-7.08%	-12.99%
Goodwill	$7.555M	$7.582M
YoY Change	-0.54%	-3.11%
Intangibles	$15.70M	$16.22M
YoY Change		-13.92%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$30.44M	$31.17M	$31.17M
YoY Change	-8.58%	-11.29%	-11.29%
TOTAL ASSETS
Total Short-Term Assets	$6.809M	$4.388M	$4.388M
Total Long-Term Assets	$30.44M	$31.17M	$31.17M
Total Assets	$37.24M	$35.56M	$35.56M
YoY Change	-1.34%	-12.99%	-12.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.404M	$3.514M	$3.514M
YoY Change	64.02%	95.18%	95.18%
Accrued Expenses	$1.301M	$1.234M	$1.996M
YoY Change	5.52%	10.52%	-5.64%
Deferred Revenue	$35.07K	$35.43K
YoY Change	-1.99%	-3.94%
Short-Term Debt	$1.562M	$1.092M	$1.092M
YoY Change	-77.16%	-88.6%	-88.6%
Long-Term Debt Due	$1.016M	$1.206M	$1.206M
YoY Change	11523.23%	13465.47%	13465.47%
Total Short-Term Liabilities	$10.92M	$7.905M	$7.905M
YoY Change	-13.13%	-43.84%	-43.84%
LONG-TERM LIABILITIES
Long-Term Debt	$63.78K	$65.04K	$65.04K
YoY Change	-94.13%	-94.19%	-94.19%
Other Long-Term Liabilities	$1.586M	$1.694M	$1.694M
YoY Change	-21.11%	-22.5%	-22.5%
Total Long-Term Liabilities	$1.649M	$1.759M	$1.759M
YoY Change	-46.72%	-46.79%	-46.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.92M	$7.905M	$7.905M
Total Long-Term Liabilities	$1.649M	$1.759M	$1.759M
Total Liabilities	$13.96M	$11.06M	$10.75M
YoY Change	-18.19%	-41.23%	-42.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.71M	-$67.03M
YoY Change	24.17%	24.55%
Common Stock	$17.29K	$15.76K
YoY Change	-56.65%	-49.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.58M	$24.82M	$24.82M
YoY Change
Total Liabilities & Shareholders Equity	$37.24M	$35.56M	$35.56M
YoY Change	-1.34%	-12.99%	-12.99%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$4.680M	-$3.160M	-$13.21M
YoY Change	18.93%	-90.38%	-59.77%
Depreciation, Depletion And Amortization	$72.60K	$582.8K	$292.0K
YoY Change	20.92%	-13.0%	-9.6%
Cash From Operating Activities	-$2.152M	-$233.3K	-$2.243M
YoY Change	673.57%	-134.53%	-61.88%
INVESTING ACTIVITIES
Capital Expenditures		$29.22K	$49.22K
YoY Change		-3752.5%	-74.12%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities		-$29.22K	-$49.22K
YoY Change		-3707.41%	-130.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.795M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.296M	463.9K	$763.9K
YoY Change	-418.78%	-104.13%	-278.84%
NET CHANGE
Cash From Operating Activities	-$2.152M	-233.3K	-$2.243M
Cash From Investing Activities		-29.22K	-$49.22K
Cash From Financing Activities	$3.296M	463.9K	$763.9K
Net Change In Cash	$1.224M	201.3K	-$1.762M
YoY Change	-194.13%	-101.91%	-71.18%
FREE CASH FLOW
Cash From Operating Activities	-$2.152M	-$233.3K	-$2.243M
Capital Expenditures		$29.22K	$49.22K
Free Cash Flow		-$262.5K	-$2.293M
YoY Change		-138.81%	-62.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001138978
CY2022Q3	NVOS	Notes And Loan Payable Current NotesAndLoanPayableCurrent		usd
CY2022Q3	NVOS	Debentures Related Parties Current DebenturesRelatedPartiesCurrent		usd
CY2023Q3	NVOS	Debentures Related Parties Noncurrent DebenturesRelatedPartiesNoncurrent		usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	NVOS	Stock Issued During Period Value Common Stock Issued To Be Held In Escrow StockIssuedDuringPeriodValueCommonStockIssuedToBeHeldInEscrow		usd
CY2022	NVOS	Issuance Of Common Stock To Be Issued IssuanceOfCommonStockToBeIssued		shares
CY2023	NVOS	Issuance Of Common Stock To Be Issued IssuanceOfCommonStockToBeIssued		shares
CY2022	NVOS	Financing Costs For Debt Extension FinancingCostsForDebtExtension		usd
CY2022	NVOS	Default Payment And Interest Paid Through Common Share Issuance DefaultPaymentAndInterestPaidThroughCommonShareIssuance		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	NVOS	Other Receivables Writeoff OtherReceivablesWriteoff		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2023	us-gaap	Proceeds From Collection Of Other Receivables ProceedsFromCollectionOfOtherReceivables		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	NVOS	Beneficial Conversion Feature Upon Issuance Of Convertible Notes BeneficialConversionFeatureUponIssuanceOfConvertibleNotes		usd
CY2022	NVOS	Debt Discount Recognized On Derivative Liability DebtDiscountRecognizedOnDerivativeLiability		usd
CY2022	NVOS	Extinguishment Of Derivative Liability Due To Conversions ExtinguishmentOfDerivativeLiabilityDueToConversions		usd
CY2022	NVOS	Debt Discount Recognized On Convertible Note DebtDiscountRecognizedOnConvertibleNote		usd
CY2022	NVOS	Common Stock Issued With Convertible Notes CommonStockIssuedWithConvertibleNotes		usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves		usd
CY2023	NVOS	Other Receivable Write Offs OtherReceivableWriteOffs		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves		usd
CY2023Q3	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet		usd
CY2022Q3	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet		usd
CY2022Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent		usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-08-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40089
CY2023	dei	Entity Registrant Name EntityRegistrantName	Novo Integrated Sciences, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3691650
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	11120 NE 2nd Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bellevue
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98004
CY2023	dei	City Area Code CityAreaCode	(206)
CY2023	dei	Local Phone Number LocalPhoneNumber	617-9797
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	NVOS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	16082780	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17291192	shares
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	416323	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2178687	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1467028	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1017405	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1106983	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	879033	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1051584	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1085335	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	346171	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	571335	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	4388089	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	5731795	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5390038	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5800648	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16218539	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18840619	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1983898	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2673934	usd
CY2023Q3	us-gaap	Goodwill Goodwill	7582483	usd
CY2022Q3	us-gaap	Goodwill Goodwill	7825844	usd
CY2023Q3	us-gaap	Assets Assets	35563047	usd
CY2022Q3	us-gaap	Assets Assets	40872840	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3513842	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1800268	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1233549	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1116125	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	382666	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	454189	usd
CY2023Q3	NVOS	Notes And Loan Payable Current NotesAndLoanPayableCurrent	277405	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	459332	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	459332	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	558668	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	9099654	usd
CY2023Q3	NVOS	Contingent Liabilities Current ContingentLiabilitiesCurrent	61767	usd
CY2022Q3	NVOS	Contingent Liabilities Current ContingentLiabilitiesCurrent	534595	usd
CY2023Q3	NVOS	Debentures Related Parties Current DebenturesRelatedPartiesCurrent	916824	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11744	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8890	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	415392	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	582088	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7904858	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14074706	usd
CY2022Q3	NVOS	Debentures Related Parties Noncurrent DebenturesRelatedPartiesNoncurrent	946250	usd
CY2023Q3	NVOS	Long Term Notes And Loan LongTermNotesAndLoan	65038	usd
CY2022Q3	NVOS	Long Term Notes And Loan LongTermNotesAndLoan	161460	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	12076	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1693577	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2185329	usd
CY2023Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1400499	usd
CY2022Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1445448	usd
CY2023Q3	us-gaap	Liabilities Liabilities	11063972	usd
CY2022Q3	us-gaap	Liabilities Liabilities	18825269	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	499000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	499000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15759325	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15759325	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3118063	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3118063	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	15760	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	3118	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	90973316	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66084887	usd
CY2023Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	91138	shares
CY2022Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	414965	shares
CY2023Q3	NVOS	Common Stock Subscribed But Unissued Subscriptions Receivable CommonStockSubscribedButUnissuedSubscriptionsReceivable	1217293	usd
CY2022Q3	NVOS	Common Stock Subscribed But Unissued Subscriptions Receivable CommonStockSubscribedButUnissuedSubscriptionsReceivable	9474807	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-357383	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	560836	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67033041	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53818489	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24815945	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22305159	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-316870	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-257588	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24499075	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22047571	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35563047	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40872840	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12572019	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11737937	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	7619304	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	6938699	usd
CY2023	us-gaap	Gross Profit GrossProfit	4952715	usd
CY2022	us-gaap	Gross Profit GrossProfit	4799238	usd
CY2023	us-gaap	Selling Expense SellingExpense	15149	usd
CY2022	us-gaap	Selling Expense SellingExpense	20702	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13490728	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14364639	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	14083531	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1357043	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	13505877	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	29825915	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8553162	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25026677	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	9027	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	169088	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	360571	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1594275	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	607589	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4757121	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5973973	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-215206	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-641643	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4716282	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8040803	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13269444	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33067480	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-22302	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13269444	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-33045178	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-54892	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-195963	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13214552	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32849215	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13269444	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-33045178	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-922609	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-431605	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14192053	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33476783	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10165548	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10165548	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2913263	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2913263	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.28
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.28
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43804155	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1329750	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1272994	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1704000	usd
CY2022	NVOS	Common Stock To Be Issued For Acquisitions CommonStockToBeIssuedForAcquisitions	1433475	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5553290	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	426690	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToNoncontrollingInterest	-431605	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-33045178	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22047571	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1795000	usd
CY2023	NVOS	Stock Issued During Period Value Cashless Exercise Of Warrants StockIssuedDuringPeriodValueCashlessExerciseOfWarrants	1421583	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	9968140	usd
CY2023	NVOS	Stock Issued During Period Value Exercise Of Warrants For Cash StockIssuedDuringPeriodValueExerciseOfWarrantsForCash	532600	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	247887	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	257994	usd
CY2023	NVOS	Beneficial Conversion Feature Upon Issuance On Convertible Debt BeneficialConversionFeatureUponIssuanceOnConvertibleDebt	164046	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1390380	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	480592	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	385335	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToNoncontrollingInterest	-922609	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13269444	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24499075	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13269444	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-33045178	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2302754	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3019253	usd
CY2023	NVOS	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	-385335	usd
CY2022	NVOS	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	-426690	usd
CY2023	NVOS	Financing Costs For Debt Extension FinancingCostsForDebtExtension	-1421583	usd
CY2023	NVOS	Default Payment And Interest Paid Through Common Share Issuance DefaultPaymentAndInterestPaidThroughCommonShareIssuance	205349	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	480592	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1329750	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	797515	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	852580	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4757121	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5973973	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-215206	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-641643	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	14083531	usd
CY2022	NVOS	Other Receivables Writeoff OtherReceivablesWriteoff	299672	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1357043	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	597191	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-457006	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	255781	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	527397	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-210382	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	369647	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1770589	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	283234	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	153598	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	38743	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-58066	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	101353	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-762852	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-806394	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2243315	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5884145	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49224	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	190168	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	57489	usd
CY2022	us-gaap	Proceeds From Collection Of Other Receivables ProceedsFromCollectionOfOtherReceivables	296138	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49224	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	163459	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	7206	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	16600	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	222780	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	37130	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10591115	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	8611	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	18435	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1285903	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	15270000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	3033888	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	5104167	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1795000	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	532600	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	763860	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-427117	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-233685	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33328	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1762364	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6114475	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2178687	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8293162	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	416323	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2178687	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	432094	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1502819	usd
CY2023	NVOS	Common Stock Issued For Convertible Debt CommonStockIssuedForConvertibleDebt	9968140	usd
CY2022	NVOS	Common Stock Issued For Convertible Debt CommonStockIssuedForConvertibleDebt	1272994	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1704000	usd
CY2023	NVOS	Warrants Issued With Convertible Notes WarrantsIssuedWithConvertibleNotes	257994	usd
CY2022	NVOS	Warrants Issued With Convertible Notes WarrantsIssuedWithConvertibleNotes	5553290	usd
CY2023	NVOS	Beneficial Conversion Feature Upon Issuance Of Convertible Notes BeneficialConversionFeatureUponIssuanceOfConvertibleNotes	164046	usd
CY2023	NVOS	Debt Discount Recognized On Derivative Liability DebtDiscountRecognizedOnDerivativeLiability	1390380	usd
CY2023	NVOS	Extinguishment Of Derivative Liability Due To Conversions ExtinguishmentOfDerivativeLiabilityDueToConversions	1390380	usd
CY2023	NVOS	Debt Discount Recognized On Convertible Note DebtDiscountRecognizedOnConvertibleNote	975024	usd
CY2023	NVOS	Common Stock Issued With Convertible Notes CommonStockIssuedWithConvertibleNotes	247887	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zueJjsnOcUNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zyOSBjnJwE64">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1357043	usd
CY2021Q3	us-gaap	Goodwill Goodwill	9488848	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	864215	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	992329	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1027670	usd
CY2022	NVOS	Other Receivable Write Offs OtherReceivableWriteOffs	299672	usd
CY2023Q3	NVOS	Other Receivable Prinicipal Amount OtherReceivablePrinicipalAmount	225924	usd
CY2023Q3	us-gaap	Interest Receivable And Other Assets InterestReceivableAndOtherAssets	73748	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	602	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1357043	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-306563	usd
CY2022Q3	us-gaap	Goodwill Goodwill	7825844	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	NVOS	Schedule Of Intangible Assets Amortized Estimated Useful Lives ScheduleOfIntangibleAssetsAmortizedEstimatedUsefulLives	<p id="xdx_892_ecustom--ScheduleOfIntangibleAssetsAmortizedEstimatedUsefulLives_za2ZHHrQEAd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets are being amortized over their estimated useful lives as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_z091S00XGKb5" style="display: none">Schedule of Intangible Assets Amortized Estimated Useful Lives</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LandUseRightsMember_z93h19oIhW2d" title="Intangible assets, estimated lives">50</span> years (the lease period)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual property</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zpgmQ4XyYwO3" title="Intangible assets, estimated lives">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znKG9U4iW8Zc" title="Intangible assets, estimated lives">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brand names</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BrandNamesMember_zzCY9eBVuJO7" title="Intangible assets, estimated lives">7</span> years</span></td></tr> </table>
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	14083531	usd
CY2022Q3	us-gaap	Goodwill Goodwill	7825844	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-243361	usd
CY2023Q3	us-gaap	Goodwill Goodwill	7582483	usd
CY2023Q3	us-gaap	Goodwill Goodwill	7582483	usd
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_84E_eus-gaap--DerivativesReportingOfDerivativeActivity_z4OhpFq5wJe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zqoa4pnJhYmb">Derivative Financial Instruments</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-922609	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-431605	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	integer
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zeHicEvYzNu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zSA5qpsDHuGe">Reclassifications</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023Q3	NVOS	Trade Receivables TradeReceivables	2223243	usd
CY2022Q3	NVOS	Trade Receivables TradeReceivables	1829475	usd
CY2023Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	108000	usd
CY2022Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	180259	usd
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2331243	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2009734	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	388391	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1259954	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	81696	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	139333	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	636896	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	507416	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	1106983	usd
CY2022Q3	us-gaap	Inventory Gross InventoryGross	1906703	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1027670	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1106983	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	879033	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	864215	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	992329	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1467028	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1017405	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	1051584	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	1085335	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1051584	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1085335	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6643247	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6805380	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1253209	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1004732	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5390038	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5800648	usd
CY2023	us-gaap	Depreciation Depreciation	292041	usd
CY2022	us-gaap	Depreciation Depreciation	323040	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23290546	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23943175	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7072007	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5102556	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16218539	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18840619	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2010713	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2696213	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2006623	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1944426	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1494169	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1288217	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	848582	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	8636522	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16218539	usd
CY2023Q3	NVOS	Accrued Liabilities Gross Current AccruedLiabilitiesGrossCurrent	961897	usd
CY2022Q3	NVOS	Accrued Liabilities Gross Current AccruedLiabilitiesGrossCurrent	884024	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	236218	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	195214	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	35434	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	36887	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1233549	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1116125	usd
CY2023Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	342443	usd
CY2022Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	161460	usd
CY2023Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	277405	usd
CY2023Q3	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	65038	usd
CY2022Q3	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	161460	usd
CY2023	NVOS	Debt Instrument Default Repayment Percentage DebtInstrumentDefaultRepaymentPercentage	0.75	pure
CY2023Q3	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.05	pure
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	277405	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	6408	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6557	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	6714	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	6878	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	38481	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	342443	usd
CY2021Q4	us-gaap	Share Price SharePrice	33.50
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	22388	shares
CY2021Q4	us-gaap	Share Price SharePrice	33.50
CY2021Q4	NVOS	Shares Adjustment Description SharesAdjustmentDescription	The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $351,240 and was determined using the Black-Scholes option pricing model with the following assumptions:
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	351240	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1875000	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1579176	usd
CY2021Q4	NVOS	Discount On Convertable Note And Additional Paid In Capital DiscountOnConvertableNoteAndAdditionalPaidInCapital	295824	usd
CY2021Q4	NVOS	Discount On Convertable Note And Additional Paid In Capital DiscountOnConvertableNoteAndAdditionalPaidInCapital	295824	usd
CY2021Q4	NVOS	Original Issue Discount OriginalIssueDiscount	375000	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	90000	usd
CY2020Q3	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	267768	usd
CY2023Q3	us-gaap	Secured Debt SecuredDebt	916824	usd
CY2022Q3	us-gaap	Secured Debt SecuredDebt	946250	usd
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y1M20D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	218240	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	36946	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.60
CY2022	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P3Y9M18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5483	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	216423	shares
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1983898	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2673934	usd
CY2023Q3	NVOS	Operating Lease Assets OperatingLeaseAssets	1983898	usd
CY2022Q3	NVOS	Operating Lease Assets OperatingLeaseAssets	2673934	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	415392	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	582088	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1693577	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2185329	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2108969	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2767417	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	579780	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	510085	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	509330	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	472291	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	254187	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	300769	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2626442	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	517473	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2108969	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	415392	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1693577	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	797515	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	852580	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	772655	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	806394	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M23D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	209457	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	209457	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	11810	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	11810	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	66	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	11744	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11744	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	499000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	499000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15759325	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15759325	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3118063	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3118063	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	522777	shares
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	580778	usd
CY2023Q3	NVOS	Common Stock Subscribed But Unissued Subscriptions Receivable CommonStockSubscribedButUnissuedSubscriptionsReceivable	1217293	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	184960	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.90
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.50
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M10D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	140577	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.32
CY2023	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P5Y9M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	45000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	371423	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.44
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M23D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	371423	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.44
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y11M23D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	16000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	371423	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	371423	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.32
CY2023Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Option Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageExercisePrice	1.32
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.72
CY2022Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Option Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageExercisePrice	14.24
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	385335	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	426690	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0374	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.54	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	238805	shares
CY2021Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	33.50
CY2022	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M13D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	605721	shares
CY2022	NVOS	Share Based Compensation Arrangements By Share Based Payment Award Non Option Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice	20.50
CY2022	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionGrantedWeightedAverageRemainingContractualTerm2	P3Y3M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	844526	shares
CY2022Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	24.18
CY2023	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1077661	shares
CY2023	NVOS	Share Based Compensation Arrangements By Share Based Payment Award Non Option Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice	1.39
CY2023	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionGrantedWeightedAverageRemainingContractualTerm2	P3Y6M3D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1115933	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	806254	shares
CY2023Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	12.05
CY2023	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm3	P3Y8M15D
CY2023Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue	106960	usd
CY2023Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisableNumber	806254	shares
CY2023Q3	NVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisableWeightedAverageExercisePrice	12.05
CY2023	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionExercisableWeightedAverageRemainingContractualTerm1	P3Y8M15D
CY2023Q3	NVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionExercisableIntrinsicValue1	106960	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-13214552	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3550349	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	233800	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3316549	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-32849215	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-8828761	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	474239	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8354522	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15839947	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12523398	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15839947	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12523398	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15839947	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12523398	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1400499	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1445448	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1400499	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1445448	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1400499	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1445448	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15839947	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12523398	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	29291	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	42273	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	398	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	66759	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1179361	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	189080	usd
CY2023Q3	NVOS	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Loan BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoan	47766	usd
CY2023Q3	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	97311	usd
CY2023	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	983925	usd
CY2023	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	983925	usd
CY2023	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	983925	usd
CY2023	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	369500	usd
CY2023	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	500000	cad
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12572019	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11737937	usd
CY2023	us-gaap	Gross Profit GrossProfit	4952715	usd
CY2022	us-gaap	Gross Profit GrossProfit	4799238	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8553162	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25026677	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2302754	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3019253	usd
CY2023	NVOS	Capital Expenditures CapitalExpenditures	49224	usd
CY2022	NVOS	Capital Expenditures CapitalExpenditures	3600	usd
CY2023	us-gaap	Interest Expense InterestExpense	360571	usd
CY2022	us-gaap	Interest Expense InterestExpense	1594275	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-13269444	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-33045178	usd
CY2023Q3	us-gaap	Assets Assets	35563047	usd
CY2022Q3	us-gaap	Assets Assets	40872840	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1467028	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1017405	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16218539	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18840619	usd
CY2023Q3	us-gaap	Goodwill Goodwill	7582483	usd
CY2022Q3	us-gaap	Goodwill Goodwill	7825844	usd
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-23-044893-index-headers.html	Edgar Link	pending
0001493152-23-044893-index.html	Edgar Link	pending
0001493152-23-044893.txt	Edgar Link	pending
0001493152-23-044893-xbrl.zip	Edgar Link	pending
ex10-54.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex23-1_002.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
logo_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvos-20230831.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nvos-20230831_def.xml	Edgar Link	unprocessable
nvos-20230831_cal.xml	Edgar Link	unprocessable
nvos-20230831_pre.xml	Edgar Link	unprocessable
nvos-20230831_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVOS
Novo Integrated Sciences, Inc. Stock $nvos

2023 Q4 Form 10-K Financial Statement

#000149315223044893 Filed on December 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVOS Novo Integrated Sciences, Inc. Stock $nvos

2023 Q4 Form 10-K Financial Statement

#000149315223044893 Filed on December 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVOS
Novo Integrated Sciences, Inc. Stock $nvos